Feline mesenchymal stem cells and supernatant inhibit reactive oxygen species production in cultured feline neutrophils.

Feline bone marrow-derived MSCs (BMMSCs), adipose-derived MSCs (AMSCs) and fibroblasts (FBs) were isolated and cultured. Tri-lineage differentiation assays and flow cytometry were used to characterize MSCs. Neutrophils (NPs) were isolated from whole blood and the NPs production of reactive oxygen reactive oxygen species (ROS) was measured.

Loss-compensated and active hyperbolic metamaterials.

We have studied the dispersion relations of multilayers of silver and a dye-doped dielectric using four methods: standard effective-medium theory (EMT), nonlocal-effect-corrected EMT, nonlinear equations based on the eigenmode method, and a spatial harmonic analysis method. We compare the validity of these methods and show that metallic losses can be greatly compensated by saturated gain. Two realizable applications are also proposed.

Ultra-thin ultra-smooth and low-loss silver films on a germanium wetting layer.

We demonstrate a method to fabricate ultra-thin, ultra-smooth and low-loss silver (Ag) films using a very thin germanium (Ge) layer as a wetting material and a rapid post-annealing treatment. The addition of a Ge wetting layer greatly reduces the surface roughness of Ag films deposited on a glass substrate by electron-beam evaporation. The percolation threshold of Ag films and the minimal thickness of a uniformly continuous Ag film were significantly reduced using a Ge wetting layer in the fabrication.

Crohn's disease and ulcerative colitis.

This column discusses the prevalence, symptoms, and treatment of Crohn's disease and ulcerative colitis and the role nurses play for these patients.

Phase I trial of sequential low-dose 5-aza-2'-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma.

Purpose: The silencing of gene expression through DNA methylation contributes to defects in antigen presentation and apoptosis in melanoma and renal cell cancer. To determine how a hypomethylating agent would modulate the toxicity and antitumor activity of immunotherapy, we initiated a phase I trial of 5-aza-2'-deoxycytidine (decitabine) plus high-dose interleukin 2 (IL-2).

Experimental Design: Patients received s.